Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
CASTRES, France, June 16, 2025 /CNW/ -- Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs.
View PDF
PFL-721 is a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor, soon to transition to dose optimization within a first-in-human trial in NSCLC. PFL-241 is a mutant-specific, brain penetrant, 4th generation EGFR inhibitor, currently in dose escalation in a first-in-human trial, to address C797S resistance mutations in NSCLC patients.
NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in approximately 14-38 percent of tumors, depending on geography. [1], [2], [3]
"With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel and differentiated precision medicines to patient populations with significant unmet needs." said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.
About Pierre Fabre Laboratories
Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care.
[1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, October 2016
[2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., August 2015
[3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, November 2015
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
16 hours ago
- Cision Canada
100 Days to 8th CIIE: Preps Harden as Global Exhibitors Eye Business Potential in China Français
SHANGHAI, /CNW/ -- Facing the complex international landscape and mounting challenges, China International Import Expo (CIIE) consistently acts as a platform for global business exchange. With only 100 days to go, the 8 th CIIE is set to take place in Shanghai from November 5 to 10. As of now, over 50 countries and international organizations have confirmed their participation in the Country Pavilion. Sweden and the United Arab Emirates will serve as guest countries of honor at the 8 th CIIE, while Kyrgyzstan will make its debut. To help global enterprises across sectors better integrate into the Chinese market, the Corporate Pavilion features six major exhibition areas—encompassing Medical Equipment and Healthcare Products, Automobile and Smart Mobility, Intelligent Industry & Information Technology, Consumer Goods, Food and Agriculture Products, and Trade in Services—and will continue hosting its Innovation Incubation Special Section. Driven by strong interest and participation from overseas companies, total booked exhibition space has surpassed 330,000 square meters, with 170 companies and 26 institutions becoming eight-time full-attendance exhibitors. Notably, this year's Corporate Pavilion introduces four fresh innovations, demonstrating its vibrant energy and vast collaboration opportunities for participants. A special section for the least-developed countries products will launch alongside an upgraded Africa products section, helping 53 diplomatic African partners leverage zero-tariff treatment to enter the Chinese market. A new section for overseas provinces and cities stands as another highlight. Focused on global premieres, a dedicated trail for exploring debuts and a section amplifying exhibitors' presence are introduced. A cross-border e-commerce platform will be established for specialized promotion, matching, and livestreaming. The 8 th Hongqiao International Economic Forum (HQF) will convene under the theme "Opening-up for New Opportunities, Cooperation for a Shared Future". Alongside the release of the World Openness Report 2025 and the latest World Openness Index, the HQF will host over 20 parallel sessions on revitalizing multilateral cooperation, empowering digital intelligence, green and sustainable development, and a more open China. Side events will retain previous categories, while people-to-people exchange activities will add a new "Charming Friends of City" zone, inviting international friendly provinces and cities to set up their booths.
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's Osimertinib Study: A Potential Game-Changer for NSCLC Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a study titled 'Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France' to evaluate the effectiveness of osimertinib in treating locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations. The study aims to assess the 36-month overall survival rate, patient characteristics, disease progression, treatment patterns, and quality of life. The intervention being tested is osimertinib, a drug used as a first-line treatment for NSCLC patients with specific genetic mutations. It is designed to target and inhibit the growth of cancer cells. This observational study employs a multicenter design, combining a cross-sectional survey and a prospective cohort model. It focuses on real-life treatment scenarios to gather comprehensive data on patient outcomes and treatment efficacy. The study began on May 12, 2021, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and ensuring timely analysis of the data collected. The study's findings could significantly impact AstraZeneca's stock performance by demonstrating the effectiveness of osimertinib, potentially boosting investor confidence. It also positions AstraZeneca competitively within the oncology market, particularly against other companies developing treatments for NSCLC. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
a day ago
- Globe and Mail
AbbVie's Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment
Abbvie ((ABBV)), Abbvie (($CC: announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie is conducting a Phase 3 clinical study titled 'A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer'. The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior treatment. The study tests two interventions: telisotuzumab vedotin, an investigational biological drug administered intravenously every two weeks, and docetaxel, an active comparator drug given intravenously every three weeks. The goal is to determine which treatment better reduces disease activity and manages adverse events. This interventional study employs a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are randomly assigned to receive either telisotuzumab vedotin or docetaxel, with approximately 698 participants expected to be enrolled globally. The study began on March 25, 2022, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and study progress. For investors, this study could significantly impact AbbVie's stock performance and investor sentiment, especially if telisotuzumab vedotin demonstrates superior efficacy and safety. Success in this trial could position AbbVie favorably against competitors in the NSCLC treatment market. The study is ongoing, and further details are available on the ClinicalTrials portal.
